rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Frank E. Thomas

Director

Company insider

Files Form 4 as: Director, Spero Therapeutics; Director, Larimar Therapeutics; Officer, Orchard Therapeutics; President & COO, Amag Pharmaceuticals; President & CEO, Critical Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
132
Buys
8
Sells
4
Bought
$124K
Sold
$2.6M
Companies
5
Companies where not an officer
2
First trade
3 Jan 2006
Last trade
23 Jun 2026
Last filed
25 Jun 2026

Companies traded

Where they are an officer
Orchard TherapeuticsOfficer · last 24 Jan 20241 buy · 0 sells
Amag PharmaceuticalsOfficer · last 23 Feb 20174 buys · 4 sells
Critical TherapeuticsDirector, Officer · last 22 Aug 20071 buy · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
SPRO Spero TherapeuticsDirector · Biotechnology · last 23 Jun 20260 buys · 0 sells
LRMR Larimar TherapeuticsDirector · Biotechnology · last 19 May 20262 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
01Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
23 Jun 2026filed 25 Jun 2026SPRO Spero TherapeuticsBiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
23 Jun 2026filed 25 Jun 2026SPRO Spero Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,000 at $0.00filing
23 Jun 2026filed 25 Jun 2026SPRO Spero Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,000 at $0.00filing
23 Jun 2026filed 25 Jun 2026SPRO Spero TherapeuticsBiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
19 May 2026filed 20 May 2026LRMR Larimar Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—55,150 at $0.00filing
19 May 2026filed 20 May 2026LRMR Larimar Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—55,150 at $0.00filing
27 Feb 2026filed 2 Mar 2026LRMR Larimar TherapeuticsBiotechnologySEC FORM 4 Bought$25K5,000 at $5.00filing
27 Feb 2026filed 2 Mar 2026LRMR Larimar TherapeuticsBiotechnologySEC FORM 4 Bought$25K5,000 at $5.00filing
12 Jun 2025filed 16 Jun 2025SPRO Spero TherapeuticsBiotechnologySEC FORM 4 Code A—20,000 at $0.00filing
13 May 2025filed 14 May 2025LRMR Larimar Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—19,000 at $0.00filing
29 May 2024filed 31 May 2024LRMR Larimar Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—19,000 at $0.00filing
29 May 2024filed 30 May 2024SPRO Spero TherapeuticsBiotechnologySEC FORM 4 Code A—20,000 at $0.00filing
14 Feb 2024filed 15 Feb 2024LRMR Larimar TherapeuticsBiotechnologySEC FORM 4 Bought$22K2,000 at $11.00filing
24 Jan 2024filed 24 Jan 2024Orchard Therapeuticsoption or derivativeSEC FORM 4 Code D—99,980 at $0.00filing
24 Jan 2024filed 24 Jan 2024Orchard Therapeuticsoption or derivativeSEC FORM 4 Code D—199,990 at $0.00filing
24 Jan 2024filed 24 Jan 2024Orchard Therapeuticsoption or derivativeSEC FORM 4 Code D—149,990 at $0.00filing
24 Jan 2024filed 24 Jan 2024Orchard Therapeuticsoption or derivativeSEC FORM 4 Code D—309,990 at $0.00filing
24 Jan 2024filed 24 Jan 2024Orchard Therapeuticsoption or derivativeSEC FORM 4 Code D—27,730 at $0.00filing
24 Jan 2024filed 24 Jan 2024Orchard Therapeuticsoption or derivativeSEC FORM 4 Code D—335,000 at $0.00filing
24 Jan 2024filed 24 Jan 2024Orchard Therapeuticsoption or derivativeSEC FORM 4 Code D—457,800 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care2
Not placed10

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.